Colestilan - 3SBio

Drug Profile

Colestilan - 3SBio

Alternative Names: SSS 21

Latest Information Update: 01 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shandong Chengchuang Pharmaceutical R&D
  • Developer 3SBio
  • Class Antihyperlipidaemics; Imidazolines; Polymers; Small molecules
  • Mechanism of Action Bile acid binding protein modulators; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypercholesterolaemia; Hyperphosphataemia

Most Recent Events

  • 28 Jan 2016 Preclinical trials in Hypercholesterolaemia in China (unspecified route)
  • 28 Jan 2016 Preclinical trials in Hyperphosphataemia in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top